Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/the-bmt-data-book-3rd-ed/munker/descriptif_2704013
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=2704013

The BMT Data Book (3rd Ed., Revised edition) Including Cellular Therapy

Langue : Anglais

Coordonnateurs : Munker Reinhold, Hildebrandt Gerhard C., Lazarus Hillard M., Atkinson Kerry

Couverture de l’ouvrage The BMT Data Book
An essential guide to the data, basic science, outcome studies and decision-making processes in blood and marrow stem cell transplantation.
This is an essential guide to the data, basic science, outcome studies and decision-making processes involved in blood and marrow stem cell transplantation. Organized according to disease types and procedures, it contains more than 100 tables, figures and algorithms that reflect up-to-date research and give guidance on the choices between different types of chemotherapy, autologous vs. allogeneic transplantation, peripheral blood vs. bone marrow stem cells, and standard vs. experimental treatments. This new edition summarizes the research of the last four years and gives mature data for all established indications, such as acute myeloid leukemia, myelodysplastic syndrome and Hodgkin and non-Hodgkin lymphomas. New chapters discuss global trends in stem cell transplantation, cellular therapies including donor lymphocytes, and pediatric neurologic and metabolic disorders. With an expanded complications section, links to electronic databases and discussion of new drugs and alternative stem cell sources, this text belongs in every transplant unit.
Preface; Part I. Basic Science: 1. Hematopoietic cell transplantation: past, present and future Reinhold Munker; 2. Basic science Reinhold Munker and Kerry Atkinson; Part II. Hematologic Malignancies: 3. Therapeutic decision making in BMT/SCT for acute myeloid leukemia Reinhold Munker, Gerhard C. Hildebrandt and Kerry Atkinson; 4. Therapeutic decision making in BMT/SCT for acute lymphoblastic leukemia Reinhold Munker, Vishwas Sakhalkar, Hillard M. Lazarus and Kerry Atkinson; 5. Therapeutic decision making in BMT/SCT for chronic myeloid leukemia and other myeloproliferative syndromes Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; 6. Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia Nebu Verghese Koshy, Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; 7. Therapeutic decision making in BMT/SCT for myelodysplasia Carolina Escobar, Reinhold Munker and Kerry Atkinson; 8. Hematopoietic cell transplantation for non-Hodgkin lymphoma Saurabh Chhabra and Ginna G. Laport; 9. Therapeutic decision making in BMT/SCT for Hodgkin lymphoma Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; 10. Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma Reinhold Munker, Oscar F. Ballester, Hillard M. Lazarus and Kerry Atkinson; 11. Therapeutic decision making in SCT for amyloidosis Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; Part III. Solid Tumors: 12. Therapeutic decision making in BMT/SCT for nonseminomatous germ cell tumor of testis (NSGCT) Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; 13. Therapeutic decision making in BMT/SCT for renal cell cancer Richard Childs and Reinhold Munker; 14. Therapeutic decision making in BMT/SCT for soft tissue sarcomas Reinhold Munker, Vishwas Sakhalkar, Hillard M. Lazarus and Kerry Atkinson; Part IV. Nonmalignant Disorders: 15. Therapeutic decision making in BMT/SCT for severe aplastic anemia Reinhold Munker, Anna Locasciulli and Kerry Atkinson; 16. Therapeutic decision making in BMT/SCT for congenital immunodeficiencies Vishwas Sakhalkar, Reinhold Munker and Kerry Atkinson; 17. Therapeutic decision making in BMT/SCT for hemoglobinopathies Shalini Shenoy, Reinhold Munker and Kerry Atkinson; 18. Hematopoietic stem cell transplantation for inborn errors of metabolism and neurodegenerative disorders Robert F. Wynn, Jaap J. Boelens and Muhammad A. Saif; 19. Therapeutic decision making in BMT/SCT for autoimmune disorders Reinhold Munker; 20. Cellular therapy Hans-Jochem Kolb, Kerry Atkinson and Reinhold Munker; Part V. Practical Aspects and Procedures: 21. Practical aspects and procedures, including conditioning protocols and haploidentical transplantation Reinhold Munker, Hillard M. Lazarus and Kerry Atkinson; 22. Umbilical cord blood as alternative allogeneic graft source: clinical banking and transplant outcomes Mary J. Laughlin and Reinhold Munker; Part VI. Complications: 23. Pathobiology of graft-versus-host disease Pavan Reddy; 24. Diagnosis and treatment of graft-versus-host-disease Daniel R. Couriel; 25. Management and prophylaxis of infections after BMT/SCT Nicholas Barber and Alison G. Freifeld; 26. Organ-related and miscellaneous complications Gerhard C. Hildebrandt, Reinhold Munker, Ullrich Duffner, Daniel Wolff, Michael Stadler, Tina Dietrich, Klemens Angstwurm, Amanda Sun, Binu Nair, Hillard M. Lazarus and Kerry Atkinson; Part VII. The BMT/SCT Pharmacopoeia: 27. The BMT/SCT pharmacopoeia Jill Comeau, Reinhold Munker and Kerry Atkinson; Part VIII. HLA-Testing and Laboratory Medicine: 28. HLA-testing and laboratory medicine Nicholas R. DiPaola, Reinhold Munker and Kerry Atkinson; Appendix: guide to the internet and literature databases relevant for bone marrow and stem cell transplantation; Index.
Reinhold Munker, MD is Associate Professor of Medicine, Department of Medicine, Division of Hematology-Oncology, Louisiana State University, Shreveport, LA, USA.
Gerhard C. Hildebrandt, MD is Associate Professor of Medicine, Department of Medicine, Division of Hematology-Oncology, Louisiana State University, Shreveport, LA, USA.
Hillard M. Lazarus, MD is a Disease Team Leader, Division of Hematology-Oncology, University Hospitals Case Medical Center, Cleveland, OH, USA.
Kerry Atkinson, MD, FRCP, FRACP is Professor of Medicine, Division of Hematology-Oncology, University of Queensland, and Head, Stem Cell Biology, Regenerative Medicine and Novel Therapeutic Anti-Cancer Agents Group, Mater Medical Research Institute, Queensland, Australia.

Date de parution :

Ouvrage de 555 p.

15.6x23.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 14 jours).

112,80 €

Ajouter au panier